### **2017 First Quarter**

# Financial Results Earnings Call Presentation






### 2017 March Statutory Financial Results

#### Non-Motor is the driver of the growth YoY based



#### **Premiums in the Market**




2016'02

#### Bank channel gained 2 pp portfolio share



#### **Premiums in the Market**



Driven by Motor products, especially by MTPL: > 40% MTPL, 30% Non Motor, 21% MOD and

9% Health.

Driven by Non Motor products:

> 77% Non Motor, 11% Health, 9% MOD, and 3% MTPL.

#### Corporate

2017'02


Driven by corporate risks and group health products:

➤ 64% Non Motor, 22% Health, 9% MTPL and 6% MOD

#### **Aksigorta's Growth**



#### **Premiums in Aksigorta**




5

#### Aksigorta has balanced product & channel mix




#### **Premiums of Aksigorta**




#### **Excellent Performance in 2017 First Quarter**





#### **Excellent Performance in 2017 First Quarter**





#### **Strong Balance Sheet Compared to Market**



Statutory Results as of 2016'12 (m TL)	TOTAL	Deferred IBNR due to Gradual Booking	Discount Income for Litigation Win Ratio	Discount Income for Cash Flow of O/S Claims
MARKET	2.185,2	716,6	722,0	746,6
Aksigorta	0	0	0	0

No deferred claims' reserve & no discount income in claims' reserve for Aksigorta, whereas the market has over 2 billion TL to be booked as loss in the future






## 2017 First Quarter Financial Results in IFRS




#### **Excellent Performance in 2017 First Quarter**









#### **Statutory and IFRS Reconciliation as of March 2017**



as of 31.03.2017	Fauit.	D9.1	
M TL	Equity	P&L	
SFRS Result	431	25	
IBNR			
EQUALIZATION	63	3	
URR	-14	7	
ULAE	-8	0	
Deferred Tax	-8	-2	
IFRS Result	464	33	






### 2017 March Investment Portfolio



#### **Investment Portfolio**







### **2017 Year End Guidance**




## Non-motor and MOD is expected to continue to be the profitable Think well live well growth engines of the market.

#### **Market UW Margin**

	Line of Business	16YE	21E		
	MOD	12%	max 10%		
motor	MTPL	-5%	-25%		
	Fire	15%	20-25%		
	Marine	53%	35-40%		
non-motor	Other	32%	20-25%		
	General Losses	40%	30-35%		
health	Health	10%	5-10%		

#### 2021 Market Profitability & Growth Outlook



#### 2017 Guidance









### **Appendix**




## **Sustainable Profitability Trend Continues with Positive Bottomline - SFRS**







#### **Combined Ratio (%)**



- 35-50m TL UW result per each quarter
- 90-97% Combined Ratio per each quarter
- 25-35m TL Net profit per each quarter

## **Statutory Results – Technical Results and Margins continue to improve**



Income Statement (million TL)	16Q1	16Q2	16Q3	16Q4	2016 YE	17Q1	17Q1/ 16Q1	17Q1/ 16Q4
Gross Written Premiums	499	471	407	518	1.896	615	23%	19%
Net Earned Premiums	245	246	262	273	1.026	286	17%	5%
Claims (net)	-190	-207	-185	-191	-729	-201	6%	5%
Commissions (net)	-47	-45	-50	-51	-193	-52	11%	3%
<b>Underwriting Result (net)</b>	8	-6	27	31	104	33	297%	6%
G&A Expenses	-34	-35	-33	-31	-132	-31	-9%	0%
Net Financial Income	22	28	29	9	88	36	65%	284%
Profit Before Tax	-4	-12	23	53	60	31	-914%	-42%
Tax	1	2	-5	-10	-12	-7	-686%	-37%
Net Profit	-3	-10	18	43	48	25	1010%	-43%
<b>Combined Ratio</b>	109%	114%	102%	97%	101%	99%	-10pp	2pp
Loss Ratio	77%	84%	71%	70%	71%	70%	-7рр	Орр
Commission Ratio	19%	18%	19%	19%	19%	18%	-1pp	-1pp
Expense Ratio	12%	12%	12%	9%	11%	11%	-1pp	2pp
UW Margin	3%	-2%	10%	11%	10%	11%	8рр	0рр

#### **Statutory Balance Sheet**





(TL Million)	16Q1	16Q2	16Q3	16Q4	17'Q1	17Q1/ 16Q1	17Q1/ 16Q4
Cash and Marketable Securities	959	1.000	1.067	1.106	1.160	21%	5%
Receivables	632	656	583	654	748	18%	14%
Other Assets	205	219	204	197	222	8%	13%
Participations	8	8	8	0	0	-100%	
Fixed Assets	59	62	63	69	67	13%	-3%
Total Assets	1.863	1.945	1.926	2.025	2.197	18%	8%
Payables	310	297	228	228	335	8%	47%
Technical Reserves	1.103	1.196	1.240	1.262	1.292	17%	2%
Other Liabilities	104	111	100	133	139	34%	5%
Total Shareholders' Equity	346	340	358	403	431	24%	7%
Total Liabilities and Equity	1.863	1.945	1.926	2.025	2.197	18%	8%

## Sustainable Profitability Trend Continues with Positive Bottomline - IFRS









#### **Combined Ratio (%)**



- 35-50m TL UW result per each quarter
- 90-95% Combined Ratio per each quarter
- 30-40m TL Net profit per each quarter

## IFRS Results – Technical Results and Margins continue to improve



Income Statement (million TL)	16Q1	16Q2	16Q3	16Q4	2016 YE	17Q1	17Q1/ 16Q1	17Q1/ 16Q4
Gross Written Premiums	499	471	407	518	1.896	615	23%	19%
Net Earned Premiums	245	246	262	273	1.026	286	17%	5%
Claims (net)	-169	-167	-185	-181	-701	-190	13%	5%
Commissions (net)	-47	-45	-50	-51	-193	-52	11%	3%
<b>Underwriting Result (net)</b>	29	35	27	41	132	44	50%	6%
G&A Expenses	-34	-34	-32	-30	-131	-30	-10%	0%
Net Financial Income	22	28	28	9	87	35	64%	294%
Profit Before Tax	17	28	23	20	88	42	147%	114%
Tax	-3	-6	-5	-4	-18	-9	188%	139%
Net Profit	14	22	18	16	71	33	138%	108%
<b>Combined Ratio</b>	100%	98%	100%	95%	98%	95%	-5pp	0рр
Loss Ratio	69%	68%	70%	66%	68%	66%	-3рр	Орр
Commission Ratio	19%	18%	19%	19%	19%	18%	-1pp	-1pp
Expense Ratio	12%	12%	10%	10%	11%	11%	-1pp	1pp
UW Margin	12%	14%	10%	15%	13%	15%	Зрр	0рр

#### **IFRS Balance Sheet**




(TL Million)	16Q1	16Q2	16Q3	16Q4	17'Q1	17Q1/ 16Q1	17Q1/ 16Q4
Cash and Marketable Securities	959	1.000	1.067	1.106	1.160	21%	5%
Receivables	632	656	583	654	748	18%	14%
Other Assets	201	206	191	190	214	6%	12%
Participations	8	8	8	0	0	-100%	
Fixed Assets	59	62	63	69	67	13%	-3%
Total Assets	1.859	1.932	1.913	2.019	2.188	18%	8%
Payables	310	297	228	228	335	8%	47%
Technical Reserves	1.080	1.132	1.176	1.231	1.250	16%	2%
Other Liabilities	104	111	100	133	139	34%	5%
Total Shareholders' Equity	365	391	409	427	464	27%	9%
Total Liabilities and Equity	1.859	1.932	1.913	2.019	2.188	18%	8%

#### Worst is over, claim reserves have doubled in 2 years




310,1 mTL 538,9 mTL 590,2 mTL




#### **MTPL Price Trends**





#### **MOD Price Trends**







#### Contact Information & Disclaimer



#### For further information please contact with;

Elif Horasan, Financial Control Manager

(T) +90 216 280 88 88

investor.relations@aksigorta.com.tr

www.aksigorta.com.tr/en/yatirimci\_iliskileri.php

Poligon Cad. Buyaka 2 Sitesi No:8, Kule:1, Kat:6 34771 Ümraniye İstanbul Türkiye

#### Disclaimer

The information and opinions contained in this document have been compiled by Aksigorta A.Ş. ("Company") from sources believed to be reliable and in good faith, but no representation or warranty, expressed or implied, is made as to their accuracy, completeness or correctness. No undue reliance may be placed for any purposes whatsoever on the information contained in this document is published for the assistance of recipients, but is not to be relied upon as authoritative or taken in substitution for the exercise of judgment by any recipient. The Company does not accept any liability whatsoever for any direct or consequential loss arising from any use of this document or its contents. This document is strictly confidential and may not be reproduced, distributed or published for any purpose. The information and opinions contained in this document have been compiled by Aksigorta A.Ş. ("Company") from sources believed to be reliable and in good faith, but no representation or warranty, expressed or implied, is made as to their accuracy, completeness or correctness. No undue reliance may be placed for any purposes whatsoever on the information contained in this presentation or on its completeness, accuracy or fairness. This document contains forward-looking statements by using such words as "may", "will", "expect", "believe", "plan" and other similar terminology that reflect the Company management's current views, expectations, assumptions and forecasts with respect to certain future events. As the actual performance of the companies may be affected by risks and uncertainties, all opinions, information and estimates contained in this document constitute the Company's current judgment and are subject to change, update, amend, supplement or otherwise alter without notice. Although it is believed that the information and analysis are correct and expectations reflected in this document are reasonable, they may be affected by a variety of variables and changes in underlying assumptions that could cause actual results to differ materially. Company does not undertake any obligation, and disclaims any duty to update or revise any forward looking statements, whether as a result of new information or future events. Neither this document nor the information contained within can construe any investment advice, invitation or an offer to buy or sell Company's shares. Company cannot guarantee that the securities described in this document constitute a suitable investment for all investors and nothing shall be taken as an inducement to any person to invest in or otherwise deal with any shares of Company and its group companies. The information contained in this document is published for the assistance of recipients, but is not to be relied upon as authoritative or taken in substitution for the exercise of judgment by any recipient. You must not distribute the information in this document to, or cause it to be used by, any person or entity in a place where its distribution or use would be unlawful. Neither Company, its board of directors, directors, managers, nor any of Its employees shall have any liability whatsoever for any direct or consequential loss arising from any use of this document or its contents.



## **THANKS**

**Presented by AKSİGORTA IR Team** 

